Compare Abbott Laboratories (ABT) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Otis Worldwide Corp — how do they compare? Abbott Laboratories trades at $109.58 (market cap $187.95B), while Otis Worldwide Corp trades at $72.77 (market cap $27.80B). The key difference: Abbott Laboratories is far larger — about 6.8× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| ABT | OTIS | |
|---|---|---|
Market Cap | $187.95B | $27.80B |
Sector | Health | Industrials |
52-Week High | $136.62 | $93.62 |
52-Week Low | $82.57 | $69.34 |
Enterprise Value | $214.96B | $35.84B |
Dividend Yield | 2.32% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Otis Worldwide (OTIS) trades at $72.87, down 1.51% over 24 hours, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings beat estimates but saw margin pressures and full-year guidance cuts. The company maintains strong service segment growth, with 9% organic sales increase, while facing headwinds in new equipment demand and labor costs. Valuation metrics show a P/E of 18.78 and P/S of 1.91, below historical averages after a 19% year-to-date decline.
Outlook is mixed: analyst consensus targets $92.50 with 47% buy ratings, but near-term risks include persistent margin compression and weak equipment sales. Long-term potential hinges on service margin expansion and modernization backlog execution, though investor sentiment remains cautious amid earnings misses and macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
